Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT06360133 Not yet recruiting - Dry Eye Clinical Trials

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

Start date: April 2024
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.

NCT ID: NCT06329791 Not yet recruiting - Dry Eye Disease Clinical Trials

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Start date: May 2024
Phase: Phase 3
Study type: Interventional

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.

NCT ID: NCT06271005 Not yet recruiting - Dry Eye Clinical Trials

Neurological Dry Eye Study Stimulating Both Lacrimal and Vagus Nerves

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This is a study on neurological dry eye disease, focusing on a patented over-the-counter supplement supporting tear production neurologically, including the lacrimal and vagus nerves.

NCT ID: NCT06235372 Not yet recruiting - Thyroid Eye Disease Clinical Trials

Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease

Start date: March 21, 2024
Phase:
Study type: Observational

To investigate corneal endothelial cell layer damage by specular microscopy in patients with thyroid eye disease

NCT ID: NCT06204848 Not yet recruiting - Floaters Clinical Trials

Imaging of Vitreous Opacities in a Canadian Population

Start date: May 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to capture imaging data of eye floaters in the population to build an imaging database to learn more about them in. Participants will imaged with an investigational ophthalmic imaging device to capture images of their floaters.

NCT ID: NCT06177639 Not yet recruiting - Eye Diseases Clinical Trials

Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging

WiSLO
Start date: August 2024
Phase:
Study type: Observational

The goal of this observational study is to test the use of a novel Widefield Confocal Scanning Laser Ophthalmoscope (WiSLO) Optimized for Pediatric and Neonatal Imaging in pediatric and adult subjects who are undergoing clinical evaluation for eye disease or are healthy adult volunteers. The main questions to answer are: - Whether WiSLO will be more comfortable and satisfactory in experience for the patient and operator than commercial alternatives. - If the quality of WiSLO near infrared images will be comparable to color fundus camera imaging across population of different ages and fundus pigmentation. Participants will have the following research procedures: - Imaging of both eyes with a research noncontact WiSLO - Imaging of both eyes with a commercially available non-contact hand held fundus camera (Volk Pictor Plus) - Likert scales for adults - Pediatric Likert scales for children - CRIES scales for infants.

NCT ID: NCT06174935 Not yet recruiting - Vitreous Floaters Clinical Trials

Low Dose Atropine for Symptomatic Vitreous Floaters

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

NCT ID: NCT06174064 Not yet recruiting - Dry Eye Syndromes Clinical Trials

BroadBand Light for the Treatment of Dry Eye Disease

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The investigators will be evaluating the use of broadband light in Dry Eye and Meibomian Gland Dysfunction.

NCT ID: NCT06158997 Not yet recruiting - Evaporative Dry Eye Clinical Trials

Safety and Effectiveness of EyePeace on Signs and Symptoms of Dry Eye Disease

Start date: December 3, 2023
Phase: N/A
Study type: Interventional

In this study, the EyePeace an eye massager will be compared with a standard-of-care warm compress treatment with evaporative dry eye disease. The objective is to asses the safety and effectiveness EyePeace eye massager is in relieving the signs and symptoms of evaporative dry eye disease.

NCT ID: NCT06089317 Not yet recruiting - Dry Eye Syndromes Clinical Trials

Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Dry eye disease (DED) is the most prevalent ocular surface disease worldwide. Standard treatments like artificial tears show limited effect. Regarding the ultrasonic atomization, the ultrasonic nebulizer produces consistent steam from the solution with a treatment effect delivered to the ocular surface. We aim to evaluate the effectiveness and safety of traditional Chinese medicine (TCM) ultrasonic atomization as an adjuvant treatment for DED. This is a randomized double-masked, active- and placebo-controlled trial. 200 subjects will be equally assigned to the herbal compound decoction(CD) group, dendrobium caulis (DC) group, houttuynia cordata (HC) group, placebo atomization(PA) group, and artificial tear (AT) group by stratified permuted block randomization. Subjects of CD, DC, HC, and PA groups will receive TCM ultrasonic atomization treatment (6 times/week). All patients will receive hypromellose 0.3% w/v lubricant eye drops for a 1-week wash-out and a 4-month follow-up period. Outcomes included non-invasive tear break-up times, corneal and conjunctival fluorescein staining, and other dry eye-related parameter examined by LipiView II Ocular Surface Interferometer, OCULUS® Keratograph 5M, and slit lamp biomicroscope evaluated by masked clinical assessors at baseline, week 1, 2, 3, 4 and month 2, 3, 4. The other subjective questionnaires like the Ocular Surface Disease Index (OSDI) questionnaire are also selected.